$IVVD

Green Julie sold $32K of IVVD

Green Julie (Chief Human Resources Officer) sold 40,780 shares of Invivyd, Inc. (IVVD) at an average of $0.78 ($0.72–$0.84) across 2 trades over 2026-08-17 to 2026-08-18 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Green Julie
Published Aug 19, 2026, 12:10 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 19, 2026, 12:42 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$IVVD
Neutral
medium confidence
Mentioned
$IVVD
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IVVDNeutralLow
01

Why it matters

The newest concrete information is the disclosed sale size, execution window, and weighted-average price range. Because it is 10b5-1 and relatively small, it is more likely to be noise than a fundamental driver.

02

Market read

A modest 10b5-1 insider sale was disclosed, which may slightly pressure sentiment but is unlikely to change valuation without other news.

03

What to watch

The filing does not indicate any change in business outlook, guidance, or financing; without additional catalysts, the transaction is mostly a sentiment datapoint.

Relevance 2/10Novelty 4/10Timing: Filed 2026-08-18 after-hours; reflects sales executed 2026-08-17 to 2026-08-18.

Background

This is an SEC Form 4 insider transaction disclosure for Invivyd, Inc. (IVVD). The insider is the Chief Human Resources Officer, and the sale is explicitly tied to a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$IVVDNeutralMedium confidence
Context

Invivyd insider Green Julie (Chief Human Resources Officer) sold about $31.7K of IVVD shares via a 10b5-1 plan on 2026-08-17 to 2026-08-18.

Expected impact

Low likelihood of a sustained price move; any reaction is likely short-lived unless accompanied by other company-specific news.

Evidence & confidence

The filing is a Form 4 insider transaction with a stated pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling. The dollar value is modest, so incremental impact should be limited absent corroborating fundamentals.

Market effects

No clear sector read-through from a single, small 10b5-1 insider sale.

None.

None.

Counterpoint

Traders may overreact to insider sales; 10b5-1 plans are often used to manage liquidity needs and reduce signaling risk.

Key entities

  • Invivyd, Inc.

    Company whose insider transaction was disclosed on Form 4.

  • Green Julie

    Chief Human Resources Officer who sold IVVD shares.

  • Rule 10b5-1 plan

    Pre-arranged plan that typically reduces interpretive weight of insider selling.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$IVVDMedAI 8/10

Invivyd launches phase 2 trial of VYD2311 for long COVID

Invivyd (NASDAQ:IVVD) initiated a Phase 2 trial of VYD2311 for Long COVID and Post-Vaccination Syndrome. The trial will enroll 130 participants and assess safety, tolerability, and efficacy over 90 days. VYD2311 has shown in vitro potency against SARS-CoV-2 variants. Initial data is expected in mid-2027. The trial is part of Invivyd’s broader REVOLUTION clinical program.

$IVVDMedAI 8/10

Invivyd, Inc. (IVVD) Begins Phase 2 Trial of VYD2311 for Long COVID/PVS

Invivyd, Inc. (IVVD) has initiated a Phase 2 trial, FLINTLOCK, to evaluate the safety and efficacy of VYD2311, a monoclonal antibody, in treating Long COVID and Post-Vaccination Syndrome. The trial involves ~130 participants and will assess high-dose VYD2311 against a placebo over 90 days. VYD2311 has shown strong antiviral potency against SARS-CoV-2 variants. Success could open a new treatment market, addressing a significant unmet need.

$IVVDMedAI 8/10

Millions live with long COVID. A trial will test an antibody as a possible treatment.

Invivyd (IVVD) and the SPEAR Study Group initiated the FLINTLOCK Phase 2 trial to test the monoclonal antibody VYD2311 for treating Long COVID and Post-Vaccination Syndrome. The trial will evaluate safety, efficacy, and pharmacokinetics over 90 days. VYD2311 has shown antiviral potency against all SARS-CoV-2 variants tested. Initial data is expected in mid-2027.

$IVVDMedAI 9/10

Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine…

Invivyd, Inc. (IVVD) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311 • VYD2311 met all primary and secondary endpoints comparing

$IVVDMedAI 8/10

Invivyd Reports VYD2311 Meets Primary Safety Endpoints In Phase 3 Trial

Invivyd (IVVD) reported that its COVID-19 monoclonal antibody VYD2311 met primary safety endpoints in the Phase 3 LIBERTY study, showing favorable safety and tolerability compared to an mRNA vaccine. The study enrolled 210 healthy adults, with 56.5% of VYD2311 recipients experiencing adverse events versus 91.4% for the vaccine. The company plans to use the data to support a BLA submission to the FDA. IVVD stock closed at $0.95, up 1.69%, and is trading at $0.99 in pre-market.

$IVVDMed

Invivyd Reports Second Quarter 2026 Financial Results and Recent

Invivyd, Inc. (IVVD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights • Achieved Q2 2026 PEMGARDA® (pemivibart) net product revenue of $14.3 million, representing 21% growth versus Q2 2025 net product revenue of $11.8 million • Completed rapid enrollme